Abstract
Pulmonary arterial hypertension (PAH) means high blood pressure in the lungs caused by obstruction in the small arteries of the lungs.The current study involves the fabrication of oral matrix sustained release tablet of bosentan monohydrate, a dual endothelin receptor antagonist, the optimisation of its in vitro release and characterisation. Methocel K4M PremiumDC2, a directly compressible HPMC grade, has been used as the sustained release polymer. Pregelatinised starch is used as a diluent and release modifier and sodium lauryl sulphate as a solubiliser. The influence of the above variables on drug release is measured using a 23 factorial design using design expert software. Surface response plots show significant interaction among the formulation variables, thus aiding in optimization of bilayer tablet.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference10 articles.
1. 1. Corris P. and Degano B.: Severe pulmonary arterial hypertension: treatment options and the bridge to transplantation. Eur Respir Rev., 2014, 23(134) 488-497.
2. 2. Gabbay E., Fraser J., McNeil K.: Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag, 2007, 3(6) 887–900.
3. 3. Weber C., Schmitt R., Birnboeck H., Hopfgartner G., van Marle S.P., Peeters P.A., Jonkman J.H., Jones C.R.: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther., 1996, 60(2) 124-137.
4. 4. Roy S., Naskar S., Kundu S., Kpoutsu K.: Formulation and evaluation of sustained release bilayer tablets of Propranolol hydrochloride. Int. J. Pharm Pharm Sci., 2015, 7(4) 264-269.
5. 5. Kumar U., Md Samiul I., Halder S., Rouf A.: Assessment of once daily sustained release hydrophilic matrix tablet of carvedilol. Dhaka Univ. J. Pharm. Sci, 2017, 16(1) 43-53.